![enter image description here][1] A community of senior and early career oncologists were asked to participate in group consultations and individual interviews to reflect on the importance of Phase 1 trials, who makes them possible, the value of networks, and the challenges and opportunities presented by the COVID-19 pandemic. Over the following components, you will see quotes and summaries of what emerged from these sessions. ### **[The Importance of Phase 1 Trials][3]** Safeguarding cancer patients and enabling future therapies with empathy - Gatekeepers - Enabling Future Therapies - Human centred - Small Scale - Limited window of opportunity/urgency - Reputation/Trust ### **[The Impact of COVID-19 on Phase 1 Trials][4]** The resilience and adaptability of cancer trialists and their network to continue patient support in the context of global disruption - Resilience - Patient experience - Networking remotely and the value of face to face contact - Accelerating change - Visibility of Trials in the public eye ### **[Who makes a Phase 1 Trial happen?][5]** Seeing cancer and the cancer patient through the perspective of the Phase 1 trialist - Lifelong learning / curiosity - Dealing with Uncertainty - Communication - Empathy - Evidence based ### **[Networks and Stakeholders: How are Networks created, and how do they evolve?][6]** Creating an optimal dynamic, leveraging skills and experiences by reaching across silos through curiosity and informal links. - Importance of informal relations and curiosity - Small scale - Leveraging diverse expertises: Creating Communities of Practice - Avoiding silos / defragmentation - Global Partnerships : Malawi & the threat of brain drain ### **[Learning from treating childhood cancer][7]** Anticipating the changes in the target population for First in Human Trials - Changing population - Redefining quality of life, and how it’s measured - Side effects ### **[Changing dynamics][8]** Being open to change - What can we learn from the current situation and what’s next - Patient involvement in trials - Changing Population - Growing size of studies and competition - Digital Data & Knowledge Management - What's next? You can view the enhanced report here: https://osf.io/azg8e/ You can download the enhanced report here: https://osf.io/azg8e/download [1]: https://mfr.de-1.osf.io/export?url=https://osf.io/4k29t/?direct%26mode=render%26action=download%26public_file=False&initialWidth=759&childId=mfrIframe&parentTitle=OSF+%7C+Firstinhuman4.jpg&parentUrl=https://osf.io/4k29t/&format=2400x2400.jpeg [2]: https://osf.io/vmxzb/ [3]: https://osf.io/9cs7w/ [4]: https://osf.io/cafju/ [5]: https://osf.io/zja6c/ [6]: https://osf.io/cp4rq/ [7]: https://osf.io/pnqhj/ [8]: https://osf.io/2fk4m/